New drug cenerimod put to the test: will it affect your heart or birth control?
NCT ID NCT04255277
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial in 97 healthy adults checks if cenerimod, an experimental drug, affects heart rhythm (QT interval) and how it interacts with birth control pills and activated charcoal. Participants receive either placebo, low or high dose cenerimod, or a control drug (moxifloxacin) to measure safety and drug levels. The goal is to gather essential safety data before testing in patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cenerimod
What this could lead to
If successful, this study could help determine safe dosing of cenerimod and understand how it interacts with other medications.
What could go wrong
This is an early-phase trial in healthy people, not patients. Results may not predict real-world safety or effectiveness in treating disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 1
Rennes, 35042, France